- Published on
Pathology – Non Alcoholic Fatty Liver Disease
• The metabolic syndrome's hepatic manifestation, which includes hyperlipidemia, poor glucose tolerance, and central obesity. Simple steatosis (fatty liver), non-alcoholic steatohepatitis (NASH), and cirrhosis are among the disorders that fall under the umbrella of non-alcoholic fatty liver disease (NAFLD).
Epidemiology: Due to increased obesity rates, this condition is very frequent and is becoming more common. • The most frequent reason for abnormal liver function tests these days. • A large number of cirrhosis cases that were previously believed to be cryptogenic are now believed to be end-stage NAFLD. The cause • The most frequent correlations are between diabetes and obesity. • Also connected to parenteral feeding and some medications.
The pathogenesis • Obesity and insulin resistance appear to be the main contributing factors. • Hepatocyte damage and fat storage are brought on by insulin resistance. • Inflammation in reaction to hepatocyte damage causes fibrosis and, in certain cases, cirrhosis.
Presentation: Abnormal liver function tests are used to identify the majority of asymptomatic cases. • Cirrhosis-related problems can occasionally be seen in patients.
The macroscopy • Cirrhotic livers are diffusely nodular; the liver is swollen, squishy, and greasy.
The study of histopathology • NASH exhibits steatosis together with the presence of enlarged hepatocytes and neutrophils; steatosis is characterized by the buildup of fat within hepatocytes without discernible inflammatory activity. Depending on the disease's stage, there may be variable fibrosis. Keep in mind that these histology results are nearly the same as those observed in alcoholic liver disease. It can occasionally be challenging to rule out alcoholic liver disease since many individuals significantly underreport their alcohol consumption. The outlook • There is extremely little chance that steatosis may develop into chronic liver disease.
• About 10–15% of NASH cases progress to cirrhosis over the course of 8 years. • Compared to individuals with cirrhosis brought on by alcoholic liver disease, those with cirrhosis brought on by nonalcoholic fatty liver disease typically have a higher survival rate.
• The metabolic syndrome's hepatic manifestation, which includes hyperlipidemia, poor glucose tolerance, and central obesity. Simple steatosis (fatty liver), non-alcoholic steatohepatitis (NASH), and cirrhosis are among the disorders that fall under the umbrella of non-alcoholic fatty liver disease (NAFLD).
Epidemiology: Due to increased obesity rates, this condition is very frequent and is becoming more common. • The most frequent reason for abnormal liver function tests these days. • A large number of cirrhosis cases that were previously believed to be cryptogenic are now believed to be end-stage NAFLD. The cause • The most frequent correlations are between diabetes and obesity. • Also connected to parenteral feeding and some medications.
The pathogenesis • Obesity and insulin resistance appear to be the main contributing factors. • Hepatocyte damage and fat storage are brought on by insulin resistance. • Inflammation in reaction to hepatocyte damage causes fibrosis and, in certain cases, cirrhosis.
Presentation: Abnormal liver function tests are used to identify the majority of asymptomatic cases. • Cirrhosis-related problems can occasionally be seen in patients.
The macroscopy • Cirrhotic livers are diffusely nodular; the liver is swollen, squishy, and greasy.
The study of histopathology • NASH exhibits steatosis together with the presence of enlarged hepatocytes and neutrophils; steatosis is characterized by the buildup of fat within hepatocytes without discernible inflammatory activity. Depending on the disease's stage, there may be variable fibrosis. Keep in mind that these histology results are nearly the same as those observed in alcoholic liver disease. It can occasionally be challenging to rule out alcoholic liver disease since many individuals significantly underreport their alcohol consumption. The outlook • There is extremely little chance that steatosis may develop into chronic liver disease.
• About 10–15% of NASH cases progress to cirrhosis over the course of 8 years. • Compared to individuals with cirrhosis brought on by alcoholic liver disease, those with cirrhosis brought on by nonalcoholic fatty liver disease typically have a higher survival rate.
0 Comments
